ArticleCommunications medicine2026
Associations of abdominal obesity and plasma fatty acids with microvascular diseases.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe independent and interactive associations of abdominal obesity and fatty acids with the risk of microvascular diseases (MVDs) are still unclear.
methodsWe conducted a prospective cohort study of 88,571 participants aged 40-69 years from the UK Biobank. Plasma fatty acids were quantified at baseline using high-throughput nuclear magnetic resonance spectroscopy and were analyzed in quartiles, with the lowest quartile of each fatty acid subtype as the reference. Cox regression models were employed to assess the associations between fatty acid levels and incident MVDs, with adjustment for relevant covariates.
resultsOver a median follow-up of 13.7 years, higher levels of total polyunsaturated fatty acids (PUFAs), n-3 PUFAs, and n-6 PUFAs are associated with a significantly lower risk of MVDs. The hazard ratios (HRs) for the highest versus lowest quartile (Q4 vs. Q1) are 0.81 (95% CI: 0.75-0.87), 0.89 (95% CI: 0.83-0.96), and 0.85 (95% CI: 0.79-0.91), respectively. Conversely, higher levels of saturated and monounsaturated fatty acids are associated with a higher risk of MVDs. Furthermore, an antagonistic additive interaction is observed between n-3 PUFAs and abdominal obesity (RERI: -0.14, 95% CI: -0.25- -0.03).
conclusionHigher plasma PUFAs are associated with a lower risk of MVDs. Furthermore, the association between n-3 PUFAs and a lower risk of MVDs is more pronounced among individuals with abdominal obesity. These findings contribute to the limited prospective evidence on the associations between plasma-specific fatty acids and MVDs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.